Skip to main content

Table 2 Heart dimensions and function

From: Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy

 

Wt/wt

Wt/wt + ATII

Db/db

Db/db + DAPA

Db/db + ATII

Db/db + ATII + DAPA

Numbers

6

6

5

4

6

6

IVS

0.9 ± 0.1

1.2 ± 0.08&

0.96 ± 0.08

0.97 ± 0.1

1.2 ± 0.1#

1.2 ± 0.2

LVPW

0.8 ± 0.05

1.1 ± 0.12&

0.9 ± 0.1

0.9 ± 0.3

1.1 ± 0.1#

1.2 ± 0.3

LVEDD

3.8 ± 0.2

3.4 ± 0.3

3.5 ± 0.5

3.7 ± 0.6

3.7 ± 0.4

3.4 ± 0.6

LVESD

2.4 ± 0.1

2.3 ± 0.3

2.1 ± 0.5

2.2 ± 0.5

2.4 ± 0.3

1.9 ± 0.5*

FS

36.2 ± 2.2

31.9 ± 4.9

39.4 ± 6.2

39.7 ± 6.3

34.9 ± 2.6

45.9 ± 6.5*

  1. * p < 0.05 vs db/db ± ATII, #p < 0.05 vs db/db, &p < 0.05 vs wt/wt
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840